ReviewThe oncologist2011
Current and emerging therapies for advanced adrenocortical carcinoma.
Review in The oncologist, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).Journal of endocrinological investigation · 2016Guideline
- Iron Oxide Nanoparticle Uptake, Toxicity, and Steroidogenesis in Adrenocortical Carcinoma Cells Using a Multicellular in vitro Model.International journal of nanomedicine · 2025Article
- Adrenocortical Cancer Cell uptake of Iron Oxide Nanoparticles.bioRxiv : the preprint server for biology · 2024Article
- Change of treatment modality and outcomes of adrenocortical carcinoma: a retrospective review of single tertiary center experience over 24 years.Gland surgery · 2022Article
- Feminizing Adrenocortical Tumors as a Rare Etiology of Isosexual/Contrasexual PseudopubertyJournal of clinical research in pediatric endocrinology · 2022Review
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial.Journal for immunotherapy of cancer · 2018Article
- Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma.Clinical and translational medicine · 2016Article
- Survival and prognostic factors for adrenocortical carcinoma: a single institution experience.BMC urology · 2015Article
- Current management options for recurrent adrenocortical carcinoma.OncoTargets and therapy · 2013Article
- Liver resection for liver metastases from nondigestive endocrine cancer: extrahepatic disease burden defines outcome.Surgery · 2012Article
- Childhood adrenocortical carcinoma: Case report and review.Indian journal of endocrinology and metabolism · 2012Article
- Current and emerging therapeutic options in adrenocortical cancer treatment.Journal of oncology · 2012Article
- Familial pediatric endocrine tumors.The oncologist · 2011Review
- Feminizing adrenocortical tumors: Literature review.Indian journal of endocrinology and metabolismReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is a rare but aggressive malignancy with a poor prognosis. Complete surgical resection offers the only potential for cure; however, even after apparently successful excision, local or metastatic recurrence is frequent. Treatment options for advanced ACC are severely limited. Mitotane is the only recognized adrenolytic therapy available; however, response rates are modest and unpredictable whereas systemic toxicities are significant. Reported responses to conventional cytotoxic chemotherapy have also been disappointing, and the rarity of ACC had hampered the ability to undertake randomized clinical studies until the establishment of the First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma. This yet-to-be reported study seeks to identify the most effective first- and second-line cytotoxic regimens. The past decade has also seen increasing research into the molecular pathogenesis of ACCs, with particular interest in the insulin-like growth factor signaling pathway. The widespread development of small molecule tyrosine kinase inhibitors in broader oncological practice is now allowing for the rational selection of targeted therapies to study in ACC. In this review, we discuss the currently available therapeutic options for patients with advanced ACC and detail the molecular rationale behind, and clinical evidence for, novel and emerging therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.